Biểu hiện da liễu của bệnh hồng cầu hình liềm: một bài tổng quan cập nhật

CDC (2020) Data & Statistics on Sickle Cell Disease. In: Centers for Disease Control and Prevention. https://www.cdc.gov/NCBDDD/sicklecell/data.html. Accessed 2 Jan 2021 Piel FB, Steinberg MH, Rees DC (2017) Sickle cell disease. N Engl J Med 376:1561–1573. https://doi.org/10.1056/nejmra1510865 GBD 2013 Mortality and Causes of Death Collaborators (2015) Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 385:117–171. https://doi.org/10.1016/S0140-6736(14)61682-2 Powars DR (1990) Sickle cell anemia and major organ failure. Hemoglobin 14:573–598. https://doi.org/10.3109/03630269009046967 Sundd P, Gladwin MT, Novelli EM (2019) Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis 14:263–292. https://doi.org/10.1146/annurev-pathmechdis-012418-012838 Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337:762–769. https://doi.org/10.1056/NEJM199709113371107 Pauling L, Itano HA (1949) Sickle cell anemia a molecular disease. Science 110:543–548. https://doi.org/10.1126/science.110.2865.543 Novelli EM, Gladwin MT (2016) Crises in sickle cell disease. Chest 149:1082–1093. https://doi.org/10.1016/j.chest.2015.12.016 Manwani D, Frenette PS (2013) Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 122:3892–3898. https://doi.org/10.1182/blood-2013-05-498311 Torres LS, Hidalgo A (2022) Neutrophils as drivers of vascular injury in sickle cell disease. Immunol Rev. https://doi.org/10.1111/imr.13146 Zhang D, Xu C, Manwani D, Frenette PS (2016) Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood 127:801–809. https://doi.org/10.1182/blood-2015-09-618538 Jones H, Morey B, Anadkat M (2013) Cutaneous manifestations of Sickle cell disease. In: ResearchGate. https://www.researchgate.net/publication/272880256_Cutaneous_Manifestations_of_Sickle_Cell_Disease. Accessed 2 Jan 2021 Trent JT, Kirsner RS (2004) Leg ulcers in sickle cell disease. Adv Skin Wound Care 17:410–416. https://doi.org/10.1097/00129334-200410000-00010 Herrick JB (2001) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. Yale J Biol Med 74:179–184 Minniti CP, Eckman J, Sebastiani P et al (2010) Leg ulcers in sickle cell disease. Am J Hematol 85:831–833. https://doi.org/10.1002/ajh.21838 Koshy M, Entsuah R, Koranda A et al (1989) Leg ulcers in patients with sickle cell disease. Blood 74:1403–1408 Serjeant GR (1974) Leg ulceration in sickle cell anemia. Arch Intern Med 133:690. https://doi.org/10.1001/archinte.1974.00320160184017 Halabi-Tawil M, Lionnet F, Girot R et al (2007) Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol 158:339–344. https://doi.org/10.1111/j.1365-2133.2007.08323.x Levine AB, Punihaole D, Levine TB (2012) Characterization of the role of nitric oxide and its clinical applications. Cardiology 122:55–68. https://doi.org/10.1159/000338150 Mack AK, Kato GJ (2006) Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol 38:1237–1243. https://doi.org/10.1016/j.biocel.2006.01.010 Mohan JS, Marshall JM, Reid HL et al (1997) Postural vasoconstriction and leg ulceration in homozygous sickle cell disease. Clin Sci Lond Engl 1979 92:153–158. https://doi.org/10.1042/cs0920153 Serjeant GR, Serjeant BE, Mohan JS, Clare A (2005) Leg ulceration in sickle cell disease: medieval medicine in a modern world. Hematol Oncol Clin N Am 19:943–956. https://doi.org/10.1016/j.hoc.2005.08.005 Edsberg LE, Black JM, Goldberg M et al (2016) Revised national pressure ulcer advisory panel pressure injury staging system: revised pressure injury staging system. J Wound Ostomy Cont Nurs 43:585–597. https://doi.org/10.1097/WON.0000000000000281 Ladizinski B, Bazakas A, Mistry N et al (2012) Sickle cell disease and leg ulcers. Adv Skin Wound Care 25:420–428. https://doi.org/10.1097/01.asw.0000419408.37323.0c Brawley OW, Cornelius LJ, Edwards LR et al (2008) National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 148:932–938. https://doi.org/10.7326/0003-4819-148-12-200806170-00220 Cackovic M, Chung C, Bolton LL, Kerstein MD (1998) Leg ulceration in the sickle cell patient. J Am Coll Surg 187:307–309. https://doi.org/10.1016/s1072-7515(98)00196-3 Grada A, Phillips T (2022) Ulcers. Dermatology for the primary care provider. Elsevier, Amsterdam, pp 310–320 Criado PR, Rivitti EA, Sotto MN, de Carvalho JF (2011) Livedoid vasculopathy as a coagulation disorder. Autoimmun Rev 10:353–360. https://doi.org/10.1016/j.autrev.2010.11.008 Majmundar VD, Kalgi B (2021) Livedoid vasculopathy. In: Nih.gov. https://www.ncbi.nlm.nih.gov/books/NBK559037/. Accessed 2 Jan 2021 Vasudevan B, Neema S, Verma R (2016) Livedoid vasculopathy: A review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol 82:478. https://doi.org/10.4103/0378-6323.183635 Alavi A, Hafner J, Dutz JP et al (2013) Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol 69:1033-1042.e1. https://doi.org/10.1016/j.jaad.2013.07.019 Reagin H, Marks E, Weis S, Susa J (2018) Livedoid vasculopathy presenting in a patient with sickle cell disease. Am J Dermatopathol 40:682–685. https://doi.org/10.1097/dad.0000000000001133 El Khoury J, Taher A, Kurban M et al (2011) Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment. Int Wound J 9:344–347. https://doi.org/10.1111/j.1742-481x.2011.00882.x Onwubalili JK (1983) Sickle cell disease and infection. J Infect 7:2–20. https://doi.org/10.1016/S0163-4453(83)90863-0 Booth C, Inusa B, Obaro SK (2010) Infection in sickle cell disease: a review. Int J Infect Dis 14:e2–e12. https://doi.org/10.1016/j.ijid.2009.03.010 Okpala IE (2007) Practical manual of haemoglobinopathies. John Wiley & Sons, Oxford Halasa NB, Shankar SM, Talbot TR et al (2007) Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 44:1428–1433. https://doi.org/10.1086/516781 Samrah S, Sweidan A, Aleshawi A, Ayesh M (2020) Fusarium induced cellulitis in an immunocompetent patient with sickle cell disease: a case report. J Investig Med High Impact Case Rep 8:232470962093430. https://doi.org/10.1177/2324709620934303 Rabodonirina M, Piens MA, Monier MF et al (1994) Fusarium infections in immunocompromised patients: case reports and literature review. Eur J Clin Microbiol Infect Dis 13:152–161. https://doi.org/10.1007/BF01982190 Kimmel GW, Lebwohl M (2018) Psoriasis: overview and diagnosis. In: Bhutani T, Liao W, Nakamura M (eds) Evidence-based psoriasis. Springer International Publishing, Cham, pp 1–16 Menter A (2016) Psoriasis and psoriatic arthritis overview. Am J Manag Care 22:s216-224 Terui T, Ozawa M, Tagami H (2000) Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop: Neutrophils in T-cell-mediated immune dermatosis and psoriasis. Exp Dermatol 9:1–10. https://doi.org/10.1034/j.1600-0625.2000.009001001.x Shao S, Fang H, Dang E et al (2019) Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk. Front Immunol 10:746. https://doi.org/10.3389/fimmu.2019.00746 Kato GJ, Piel FB, Reid CD et al (2018) Sickle cell disease. Nat Rev Dis Primer 4:18010. https://doi.org/10.1038/nrdp.2018.10 de Azevedo JTC, Malmegrim KCR (2020) Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunol Lett 224:1–11. https://doi.org/10.1016/j.imlet.2020.04.012 Pulusani S, McMurray SL, Jensen K, Jones AV (2019) Psoriasis treatment in patients with sickle cell disease. Cutis 103:93–94 Francis RB, Haywood LJ (1992) Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc 84:611–615 Senet P, Combemale P, Debure C et al (2012) Malignancy and chronic leg ulcers: the value of systematic wound biopsies: a prospective, multicenter, cross-sectional study. Arch Dermatol 148:704–708. https://doi.org/10.1001/archdermatol.2011.3362 Asuquo ME, Ikpeme IA, Ebughe G, Bassey EE (2010) Marjolin’s ulcer: Sequelae of mismanaged chronic cutaneous ulcers. Adv Skin Wound Care 23:414–416. https://doi.org/10.1097/01.ASW.0000383211.18782.2a Soutou B, Senet P, Lionnet F et al (2020) Sickle cell disease induces resistance to cutaneous carcinogenesis. Orphanet J Rare Dis. https://doi.org/10.1186/s13023-020-1341-9 Lanzkron S, Strouse JJ, Wilson R et al (2008) Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 148:939. https://doi.org/10.7326/0003-4819-148-12-200806170-00221 Pule GD, Mowla S, Novitzky N et al (2015) A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol 8:669–679. https://doi.org/10.1586/17474086.2015.1078235 Steinberg MH, Barton F, Castro O et al (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645–1651. https://doi.org/10.1001/jama.289.13.1645 Chaine B, Neonato M-G, Girot R, Aractingi S (2001) Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 137:467–470 Wong TE, Brandow AM, Lim W, Lottenberg R (2014) Update on the use of hydroxyurea therapy in sickle cell disease. Blood 124:3850–3857. https://doi.org/10.1182/blood-2014-08-435768 Latagliata R, Spadea A, Cedrone M et al (2012) Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 118:404–409. https://doi.org/10.1002/cncr.26194